JP2013500718A - 細胞リプログラミングを特徴付けかつこれを使用する方法 - Google Patents
細胞リプログラミングを特徴付けかつこれを使用する方法 Download PDFInfo
- Publication number
- JP2013500718A JP2013500718A JP2012522953A JP2012522953A JP2013500718A JP 2013500718 A JP2013500718 A JP 2013500718A JP 2012522953 A JP2012522953 A JP 2012522953A JP 2012522953 A JP2012522953 A JP 2012522953A JP 2013500718 A JP2013500718 A JP 2013500718A
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- biosensor
- marker
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000008672 reprogramming Effects 0.000 title claims description 88
- 210000004027 cell Anatomy 0.000 claims abstract description 783
- 238000000034 method Methods 0.000 claims abstract description 189
- 210000000130 stem cell Anatomy 0.000 claims abstract description 140
- 239000003550 marker Substances 0.000 claims description 109
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 81
- 230000004069 differentiation Effects 0.000 claims description 68
- 210000002569 neuron Anatomy 0.000 claims description 47
- 229960003638 dopamine Drugs 0.000 claims description 41
- 102000005962 receptors Human genes 0.000 claims description 40
- 108020003175 receptors Proteins 0.000 claims description 40
- 230000036755 cellular response Effects 0.000 claims description 36
- 230000003287 optical effect Effects 0.000 claims description 34
- 230000037361 pathway Effects 0.000 claims description 34
- 210000001519 tissue Anatomy 0.000 claims description 33
- 230000024245 cell differentiation Effects 0.000 claims description 25
- 238000012258 culturing Methods 0.000 claims description 21
- 238000003384 imaging method Methods 0.000 claims description 20
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims description 18
- -1 SFLLR-amide Chemical compound 0.000 claims description 17
- 210000005064 dopaminergic neuron Anatomy 0.000 claims description 17
- 229940044601 receptor agonist Drugs 0.000 claims description 17
- 239000000018 receptor agonist Substances 0.000 claims description 17
- 239000000556 agonist Substances 0.000 claims description 16
- 239000012190 activator Substances 0.000 claims description 15
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 14
- 102400000975 Neuropeptide B-23 Human genes 0.000 claims description 14
- 101800003751 Neuropeptide B-23 Proteins 0.000 claims description 14
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 14
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 14
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims description 14
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 14
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 claims description 12
- 150000003431 steroids Chemical class 0.000 claims description 12
- 229960005309 estradiol Drugs 0.000 claims description 11
- 210000003061 neural cell Anatomy 0.000 claims description 11
- 230000005754 cellular signaling Effects 0.000 claims description 10
- 229940000406 drug candidate Drugs 0.000 claims description 10
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 10
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 10
- 210000004248 oligodendroglia Anatomy 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims description 9
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims description 9
- 102400000242 Dynorphin A(1-17) Human genes 0.000 claims description 8
- 108010065372 Dynorphins Proteins 0.000 claims description 8
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims description 8
- 229960004373 acetylcholine Drugs 0.000 claims description 8
- 210000001130 astrocyte Anatomy 0.000 claims description 8
- JMNJYGMAUMANNW-FIXZTSJVSA-N dynorphin a Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 JMNJYGMAUMANNW-FIXZTSJVSA-N 0.000 claims description 8
- 229930182833 estradiol Natural products 0.000 claims description 8
- 239000003223 protective agent Substances 0.000 claims description 8
- HOLQXBRPSSZJMZ-FGRXCANLSA-N (2s)-n-[(2s)-1-[[(2s)-6-amino-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-6-amino-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxop Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O HOLQXBRPSSZJMZ-FGRXCANLSA-N 0.000 claims description 7
- 102400000345 Angiotensin-2 Human genes 0.000 claims description 7
- 101800000733 Angiotensin-2 Proteins 0.000 claims description 7
- 102000018746 Apelin Human genes 0.000 claims description 7
- 108010052412 Apelin Proteins 0.000 claims description 7
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 7
- 102400000686 Endothelin-1 Human genes 0.000 claims description 7
- 101800004490 Endothelin-1 Proteins 0.000 claims description 7
- 102000016359 Fibronectins Human genes 0.000 claims description 7
- 108010067306 Fibronectins Proteins 0.000 claims description 7
- 108010088406 Glucagon-Like Peptides Proteins 0.000 claims description 7
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims description 7
- 102000002512 Orexin Human genes 0.000 claims description 7
- 102000003923 Protein Kinase C Human genes 0.000 claims description 7
- 108090000315 Protein Kinase C Proteins 0.000 claims description 7
- 229960005305 adenosine Drugs 0.000 claims description 7
- BWVPHIKGXQBZPV-QKFDDRBGSA-N apelin Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCSC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 BWVPHIKGXQBZPV-QKFDDRBGSA-N 0.000 claims description 7
- 230000035800 maturation Effects 0.000 claims description 7
- 108060005714 orexin Proteins 0.000 claims description 7
- OFNHNCAUVYOTPM-IIIOAANCSA-N orexin-a Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N2)[C@@H](C)O)=O)CSSC1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NC(=O)CC1)C1=CNC=N1 OFNHNCAUVYOTPM-IIIOAANCSA-N 0.000 claims description 7
- 229940063675 spermine Drugs 0.000 claims description 7
- 229960003732 tyramine Drugs 0.000 claims description 7
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 claims description 6
- XCGMILZGRGEWHL-UHFFFAOYSA-N CCC(C)C(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC3=CC=CC=C3)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCSC)C(=O)NC(CCCCN)C(=O)NC(CC4=CNC5=CC=CC=C54)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CO)C(=O)NC(CC(=O)O)C(=O)NCC(=O)NCC(=O)NC(CC6=CC=C(C=C6)OP(=O)(O)O)C(=O)NC(CCSC)C(=O)NC(CC(=O)O)C(=O)NC(CCSC)C(=O)NC(CO)C(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCCNC(=N)N)N Chemical compound CCC(C)C(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC3=CC=CC=C3)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCSC)C(=O)NC(CCCCN)C(=O)NC(CC4=CNC5=CC=CC=C54)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CO)C(=O)NC(CC(=O)O)C(=O)NCC(=O)NCC(=O)NC(CC6=CC=C(C=C6)OP(=O)(O)O)C(=O)NC(CCSC)C(=O)NC(CC(=O)O)C(=O)NC(CCSC)C(=O)NC(CO)C(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCCNC(=N)N)N XCGMILZGRGEWHL-UHFFFAOYSA-N 0.000 claims description 6
- 102400001103 Neurotensin Human genes 0.000 claims description 6
- 101800001814 Neurotensin Proteins 0.000 claims description 6
- 108091000080 Phosphotransferase Proteins 0.000 claims description 6
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 6
- 230000002973 anti-dopamine Effects 0.000 claims description 6
- 238000012512 characterization method Methods 0.000 claims description 6
- 238000011065 in-situ storage Methods 0.000 claims description 6
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 claims description 6
- 210000002894 multi-fate stem cell Anatomy 0.000 claims description 6
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 claims description 6
- 102000020233 phosphotransferase Human genes 0.000 claims description 6
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 claims description 5
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 claims description 5
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 5
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 5
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 5
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 claims description 5
- 101710151321 Melanostatin Proteins 0.000 claims description 5
- 102400000064 Neuropeptide Y Human genes 0.000 claims description 5
- 102000003797 Neuropeptides Human genes 0.000 claims description 5
- 108090000189 Neuropeptides Proteins 0.000 claims description 5
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 5
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 5
- 102100027467 Pro-opiomelanocortin Human genes 0.000 claims description 5
- 102100029097 Urotensin-2 Human genes 0.000 claims description 5
- 101710095163 Urotensin-2 Proteins 0.000 claims description 5
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims description 5
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 claims description 5
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 claims description 5
- HFNHAPQMXICKCF-USJMABIRSA-N urotensin-ii Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@@H](C(C)C)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)[C@@H](C)O HFNHAPQMXICKCF-USJMABIRSA-N 0.000 claims description 5
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 claims description 5
- 229940080349 GPR agonist Drugs 0.000 claims description 4
- 101000621371 Homo sapiens WD and tetratricopeptide repeats protein 1 Proteins 0.000 claims description 4
- 101000892274 Human adenovirus C serotype 2 Adenovirus death protein Proteins 0.000 claims description 4
- 101000820656 Rattus norvegicus Seminal vesicle secretory protein 4 Proteins 0.000 claims description 4
- PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 claims description 4
- 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 claims description 4
- 230000004075 alteration Effects 0.000 claims description 4
- 230000021164 cell adhesion Effects 0.000 claims description 4
- 238000000572 ellipsometry Methods 0.000 claims description 4
- 239000003248 enzyme activator Substances 0.000 claims description 4
- 230000004031 neuronal differentiation Effects 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 101150016042 udp gene Proteins 0.000 claims description 4
- XMGNJVXBPZAETK-UHFFFAOYSA-N 2,5-dihydroxy-3-[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]-6-[7-(3-methylbut-2-enyl)-1h-indol-3-yl]cyclohexa-2,5-diene-1,4-dione Chemical compound C1=CC=C2C(C=3C(=O)C(O)=C(C(C=3O)=O)C=3C=4C=CC=C(C=4NC=3)CC=C(C)C)=C(C(C)(C)C=C)NC2=C1 XMGNJVXBPZAETK-UHFFFAOYSA-N 0.000 claims description 3
- 102000002298 Purinergic P2Y Receptors Human genes 0.000 claims description 3
- 108010000818 Purinergic P2Y Receptors Proteins 0.000 claims description 3
- 230000003698 anagen phase Effects 0.000 claims description 3
- 230000008668 cellular reprogramming Effects 0.000 claims description 3
- 230000003828 downregulation Effects 0.000 claims description 3
- 239000002532 enzyme inhibitor Substances 0.000 claims description 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims description 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims description 3
- 108050000742 Orexin Receptor Proteins 0.000 claims description 2
- 102000008834 Orexin receptor Human genes 0.000 claims description 2
- 102000026557 Urotensins Human genes 0.000 claims description 2
- 108010011107 Urotensins Proteins 0.000 claims description 2
- 239000000780 urotensin Substances 0.000 claims description 2
- DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 claims 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 abstract description 3
- 239000003446 ligand Substances 0.000 description 57
- 239000000203 mixture Substances 0.000 description 51
- 230000004044 response Effects 0.000 description 50
- 230000001413 cellular effect Effects 0.000 description 36
- 238000003556 assay Methods 0.000 description 34
- 238000004113 cell culture Methods 0.000 description 31
- 239000002609 medium Substances 0.000 description 31
- 108090000623 proteins and genes Proteins 0.000 description 28
- 102000007547 Laminin Human genes 0.000 description 26
- 108010085895 Laminin Proteins 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 25
- 239000002904 solvent Substances 0.000 description 25
- 238000002836 resonant waveguide grating Methods 0.000 description 24
- 230000008569 process Effects 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 23
- 239000000126 substance Substances 0.000 description 22
- 239000000463 material Substances 0.000 description 21
- 239000010410 layer Substances 0.000 description 20
- 201000010099 disease Diseases 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 230000008859 change Effects 0.000 description 15
- 210000001671 embryonic stem cell Anatomy 0.000 description 15
- 230000001537 neural effect Effects 0.000 description 15
- 210000005155 neural progenitor cell Anatomy 0.000 description 15
- 239000003102 growth factor Substances 0.000 description 14
- 239000002131 composite material Substances 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 238000012216 screening Methods 0.000 description 13
- 210000001178 neural stem cell Anatomy 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- 230000009471 action Effects 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 230000001605 fetal effect Effects 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 238000012423 maintenance Methods 0.000 description 11
- 150000003384 small molecules Chemical class 0.000 description 11
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 10
- 210000004504 adult stem cell Anatomy 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 230000036961 partial effect Effects 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 108050004812 Dopamine receptor Proteins 0.000 description 8
- 102000015554 Dopamine receptor Human genes 0.000 description 8
- 230000006399 behavior Effects 0.000 description 8
- 238000000423 cell based assay Methods 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- 239000012981 Hank's balanced salt solution Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 7
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 7
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000007876 drug discovery Methods 0.000 description 7
- 210000002257 embryonic structure Anatomy 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 101710202239 Tubulin beta-3 chain Proteins 0.000 description 6
- 210000004748 cultured cell Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000001654 germ layer Anatomy 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 210000001082 somatic cell Anatomy 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 230000002123 temporal effect Effects 0.000 description 6
- JKNOYWVMHPMBEL-UNXLUWIOSA-N (3z)-2-amino-4-(3,4,5-trihydroxyphenyl)buta-1,3-diene-1,1,3-tricarbonitrile Chemical compound N#CC(C#N)=C(N)\C(C#N)=C\C1=CC(O)=C(O)C(O)=C1 JKNOYWVMHPMBEL-UNXLUWIOSA-N 0.000 description 5
- YOILXOMTHPUMRG-JSGCOSHPSA-N (4as,10bs)-4-propyl-3,4a,5,10b-tetrahydro-2h-chromeno[4,3-b][1,4]oxazin-9-ol Chemical compound C1=C(O)C=C2[C@@H]3OCCN(CCC)[C@H]3COC2=C1 YOILXOMTHPUMRG-JSGCOSHPSA-N 0.000 description 5
- 241000283707 Capra Species 0.000 description 5
- 101150049660 DRD2 gene Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 239000012131 assay buffer Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000022131 cell cycle Effects 0.000 description 5
- 230000032823 cell division Effects 0.000 description 5
- 230000033077 cellular process Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000003291 dopaminomimetic effect Effects 0.000 description 5
- 238000007877 drug screening Methods 0.000 description 5
- 230000005672 electromagnetic field Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 229960001340 histamine Drugs 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- SUHGRZPINGKYNV-GJZGRUSLSA-N (1R,3S)-1-(aminomethyl)-3-phenyl-3,4-dihydro-1H-2-benzopyran-5,6-diol Chemical compound C1([C@H]2O[C@H](C3=CC=C(O)C(O)=C3C2)CN)=CC=CC=C1 SUHGRZPINGKYNV-GJZGRUSLSA-N 0.000 description 4
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 4
- 102000038030 PI3Ks Human genes 0.000 description 4
- 108091007960 PI3Ks Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000036982 action potential Effects 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 4
- 210000003981 ectoderm Anatomy 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000000592 Artificial Cell Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 108090000862 Ion Channels Proteins 0.000 description 3
- 102000004310 Ion Channels Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 206010043276 Teratoma Diseases 0.000 description 3
- 206010044565 Tremor Diseases 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 210000004958 brain cell Anatomy 0.000 description 3
- 210000004413 cardiac myocyte Anatomy 0.000 description 3
- 230000004956 cell adhesive effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000030944 contact inhibition Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 210000002242 embryoid body Anatomy 0.000 description 3
- 210000001900 endoderm Anatomy 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000001259 mesencephalon Anatomy 0.000 description 3
- 210000003716 mesoderm Anatomy 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000009256 replacement therapy Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001360 synchronised effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229940098778 Dopamine receptor agonist Drugs 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 102000004300 GABA-A Receptors Human genes 0.000 description 2
- 108090000839 GABA-A Receptors Proteins 0.000 description 2
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
- 101000848724 Homo sapiens Rap guanine nucleotide exchange factor 3 Proteins 0.000 description 2
- 102100033467 L-selectin Human genes 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 102100034584 Rap guanine nucleotide exchange factor 3 Human genes 0.000 description 2
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000005059 dormancy Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940121647 egfr inhibitor Drugs 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000002064 heart cell Anatomy 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000009878 intermolecular interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000013307 optical fiber Substances 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001991 pathophysiological effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000004038 photonic crystal Substances 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000036647 reaction Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 230000002227 vasoactive effect Effects 0.000 description 2
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- IVVNZDGDKPTYHK-JTQLQIEISA-N 1-cyano-2-[(2s)-3,3-dimethylbutan-2-yl]-3-pyridin-4-ylguanidine Chemical compound CC(C)(C)[C@H](C)N=C(NC#N)NC1=CC=NC=C1 IVVNZDGDKPTYHK-JTQLQIEISA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- ZFGMCJAXIZTVJA-UHFFFAOYSA-N 2-methyl-2-(methylsulfanyl)propanal oxime Chemical compound CSC(C)(C)C=NO ZFGMCJAXIZTVJA-UHFFFAOYSA-N 0.000 description 1
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- SDQJYYGODYRPBR-UHFFFAOYSA-N 8-bromo-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol;hydrobromide Chemical compound Br.C1N(C)CCC2=CC(Br)=C(O)C=C2C1C1=CC=CC=C1 SDQJYYGODYRPBR-UHFFFAOYSA-N 0.000 description 1
- 108091008803 APLNR Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229940122614 Adenosine receptor agonist Drugs 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000016555 Apelin receptors Human genes 0.000 description 1
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 1
- 101710151768 Aromatic-L-amino-acid decarboxylase Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100025222 CD63 antigen Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 1
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102100036949 Developmental pluripotency-associated protein 2 Human genes 0.000 description 1
- 102100037126 Developmental pluripotency-associated protein 4 Human genes 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000289669 Erinaceus europaeus Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229940121909 GABA receptor agonist Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 229940117892 Glutamate receptor agonist Drugs 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102100027875 Homeobox protein Nkx-2.5 Human genes 0.000 description 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
- 101000804948 Homo sapiens Developmental pluripotency-associated protein 2 Proteins 0.000 description 1
- 101000881868 Homo sapiens Developmental pluripotency-associated protein 4 Proteins 0.000 description 1
- 101000632197 Homo sapiens Homeobox protein Nkx-2.5 Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101000984044 Homo sapiens LIM homeobox transcription factor 1-beta Proteins 0.000 description 1
- 101000980823 Homo sapiens Leukocyte surface antigen CD53 Proteins 0.000 description 1
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 1
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 1
- 101001120813 Homo sapiens Myosin regulatory light chain 2, atrial isoform Proteins 0.000 description 1
- 101000603407 Homo sapiens Neuropeptides B/W receptor type 1 Proteins 0.000 description 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- 102100025457 LIM homeobox transcription factor 1-beta Human genes 0.000 description 1
- 102100024221 Leukocyte surface antigen CD53 Human genes 0.000 description 1
- 206010061223 Ligament injury Diseases 0.000 description 1
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 description 1
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 description 1
- 108010018650 MEF2 Transcription Factors Proteins 0.000 description 1
- 102000029828 Melanin-concentrating hormone receptor Human genes 0.000 description 1
- 108010047068 Melanin-concentrating hormone receptor Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 229940121743 Muscarinic receptor agonist Drugs 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100039229 Myocyte-specific enhancer factor 2C Human genes 0.000 description 1
- 102100026057 Myosin regulatory light chain 2, atrial isoform Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102100038842 Neuropeptide B Human genes 0.000 description 1
- 102100038847 Neuropeptides B/W receptor type 1 Human genes 0.000 description 1
- 102100037590 Neurotensin/neuromedin N Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 229940121954 Opioid receptor agonist Drugs 0.000 description 1
- 229940121884 Orexin receptor agonist Drugs 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- 108700023400 Platelet-activating factor receptors Proteins 0.000 description 1
- 102100024304 Protachykinin-1 Human genes 0.000 description 1
- 229940124065 Protease-activated receptor agonist Drugs 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102400000096 Substance P Human genes 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 208000021945 Tendon injury Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 101710101305 Transducin-like enhancer protein 1 Proteins 0.000 description 1
- 102100039362 Transducin-like enhancer protein 1 Human genes 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102100026893 Troponin T, cardiac muscle Human genes 0.000 description 1
- 101710165323 Troponin T, cardiac muscle Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108010075974 Vasoactive Intestinal Peptide Receptors Proteins 0.000 description 1
- 102000012088 Vasoactive Intestinal Peptide Receptors Human genes 0.000 description 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 102000052549 Wnt-3 Human genes 0.000 description 1
- 108700020985 Wnt-3 Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- SCJNCDSAIRBRIA-DOFZRALJSA-N arachidonyl-2'-chloroethylamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCCl SCJNCDSAIRBRIA-DOFZRALJSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000004703 blastocyst inner cell mass Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000012820 cell cycle checkpoint Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000033026 cell fate determination Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229940126513 cyclase activator Drugs 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000012362 drug development process Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 210000001705 ectoderm cell Anatomy 0.000 description 1
- 210000004039 endoderm cell Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000006277 exogenous ligand Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000000604 fetal stem cell Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 210000001650 focal adhesion Anatomy 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 239000003574 free electron Substances 0.000 description 1
- 210000001222 gaba-ergic neuron Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003823 glutamate receptor agonist Substances 0.000 description 1
- 230000000848 glutamatergic effect Effects 0.000 description 1
- 210000001362 glutamatergic neuron Anatomy 0.000 description 1
- 210000004517 glycocalyx Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000009629 growth pathway Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002847 impedance measurement Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000006662 intracellular pathway Effects 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 230000025350 membrane depolarization involved in regulation of action potential Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 108700024542 myc Genes Proteins 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 108010085094 neuropeptide B Proteins 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000000263 nonmitogenic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000003402 opiate agonist Substances 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000004663 osteoprogenitor cell Anatomy 0.000 description 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229960002310 pinacidil Drugs 0.000 description 1
- 238000009832 plasma treatment Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 102000030769 platelet activating factor receptor Human genes 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000026447 protein localization Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 208000022074 proximal spinal muscular atrophy Diseases 0.000 description 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000036390 resting membrane potential Effects 0.000 description 1
- 239000007320 rich medium Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010374 somatic cell nuclear transfer Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000002287 time-lapse microscopy Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23039809P | 2009-07-31 | 2009-07-31 | |
| US61/230,398 | 2009-07-31 | ||
| US23080109P | 2009-08-03 | 2009-08-03 | |
| US61/230,801 | 2009-08-03 | ||
| PCT/US2010/043336 WO2011014485A2 (en) | 2009-07-31 | 2010-07-27 | Methods to characterize cell reprogramming and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2013500718A true JP2013500718A (ja) | 2013-01-10 |
Family
ID=42556980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012522953A Pending JP2013500718A (ja) | 2009-07-31 | 2010-07-27 | 細胞リプログラミングを特徴付けかつこれを使用する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110028345A1 (OSRAM) |
| EP (1) | EP2460008A2 (OSRAM) |
| JP (1) | JP2013500718A (OSRAM) |
| CN (1) | CN102549430A (OSRAM) |
| IN (1) | IN2012DN00852A (OSRAM) |
| WO (1) | WO2011014485A2 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11229789B2 (en) | 2013-05-30 | 2022-01-25 | Neurostim Oab, Inc. | Neuro activator with controller |
| EP3441109A1 (en) | 2013-05-30 | 2019-02-13 | Graham H. Creasey | Flexible dermal patch for a topical nerve stimulator system |
| US20170363614A1 (en) * | 2014-12-22 | 2017-12-21 | Enumeral Biomedical Holdings, Inc. | Methods For Screening Therapeutic Compounds |
| US11077301B2 (en) | 2015-02-21 | 2021-08-03 | NeurostimOAB, Inc. | Topical nerve stimulator and sensor for bladder control |
| KR102562469B1 (ko) | 2017-11-07 | 2023-08-01 | 뉴로스팀 오에이비, 인크. | 적응형 회로를 구비한 비침습성 신경 활성화기 |
| CN113167793A (zh) * | 2018-11-20 | 2021-07-23 | 豪夫迈·罗氏有限公司 | 用于在传感器表面上接种细胞的方法 |
| CN111239130A (zh) * | 2018-11-28 | 2020-06-05 | 中国科学院大连化学物理研究所 | 一种无标记内皮素受体细胞模型构建和筛选的方法及应用 |
| WO2020264214A1 (en) | 2019-06-26 | 2020-12-30 | Neurostim Technologies Llc | Non-invasive nerve activator with adaptive circuit |
| CN112345745A (zh) * | 2019-08-07 | 2021-02-09 | 中国科学院大连化学物理研究所 | 无标记血管紧张素ⅱ受体细胞模型构建和筛选方法及应用 |
| EP4017580A4 (en) | 2019-12-16 | 2023-09-06 | Neurostim Technologies LLC | NON-INVASIVE NERVE ACTIVATOR WITH AMPLIFIED CHARGE DISTRIBUTION |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040147045A1 (en) * | 2002-10-29 | 2004-07-29 | Gentel Biosurfaces, Inc. | Signal molecule arrays |
| US8076090B2 (en) * | 2005-04-05 | 2011-12-13 | Corning Incorporated | Label free biosensors and cells |
| EP2064542B1 (en) * | 2007-04-19 | 2011-08-17 | Corning Incorporated | Live-cell signals of pathogen intrusion and methods thereof |
| US20090181409A1 (en) * | 2008-01-10 | 2009-07-16 | Ye Fang | Optical biosensor method for cell-cell interaction |
-
2010
- 2010-07-16 US US12/837,729 patent/US20110028345A1/en not_active Abandoned
- 2010-07-27 WO PCT/US2010/043336 patent/WO2011014485A2/en not_active Ceased
- 2010-07-27 EP EP10738126A patent/EP2460008A2/en not_active Withdrawn
- 2010-07-27 CN CN2010800430122A patent/CN102549430A/zh active Pending
- 2010-07-27 JP JP2012522953A patent/JP2013500718A/ja active Pending
- 2010-07-27 IN IN852DEN2012 patent/IN2012DN00852A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102549430A (zh) | 2012-07-04 |
| US20110028345A1 (en) | 2011-02-03 |
| WO2011014485A3 (en) | 2011-03-24 |
| IN2012DN00852A (OSRAM) | 2015-07-10 |
| EP2460008A2 (en) | 2012-06-06 |
| WO2011014485A2 (en) | 2011-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013500718A (ja) | 細胞リプログラミングを特徴付けかつこれを使用する方法 | |
| Bhattacharya et al. | High efficiency differentiation of human pluripotent stem cells to cardiomyocytes and characterization by flow cytometry | |
| CN110709092B (zh) | 用于产生人少突胶质细胞和研究体外髓鞘形成的个性化3d神经培养系统 | |
| Lu et al. | Engineering a functional three-dimensional human cardiac tissue model for drug toxicity screening | |
| CN102460171A (zh) | 细胞群和混合细胞群变化的检测 | |
| US8658353B2 (en) | Liver cell toxicity assay | |
| Geng et al. | Tracking the differentiation status of human neural stem cells through label-free Raman spectroscopy and machine learning-based analysis | |
| CN114630900A (zh) | 用于研究皮质-纹状体-中脑神经通路的人细胞模型 | |
| Pesl et al. | Phenotypic assays for analyses of pluripotent stem cell–derived cardiomyocytes | |
| Kim et al. | Anti-fibrotic effect of a selective estrogen receptor modulator in systemic sclerosis | |
| WO2021119209A1 (en) | In vitro expansion of dopaminergic subtype neuronal progenitors derived from pluripotent stem cells | |
| Fröhlich | Issues with cancer spheroid models in therapeutic drug screening | |
| Li et al. | Label-free evaluation of maturation and hepatotoxicity of human iPSC-derived hepatocytes using hyperspectral Raman imaging | |
| US12247195B2 (en) | Microfluidic system and method of use thereof | |
| Wu et al. | Pluripotent stem cells for target organ developmental toxicity testing | |
| Zang et al. | An engineered mouse embryonic stem cell model with survivin as a molecular marker and EGFP as the reporter for high throughput screening of embryotoxic chemicals in vitro | |
| Gorelik et al. | Non-invasive imaging of stem cells by scanning ion conductance microscopy: future perspective | |
| Harrill | Human-derived neurons and neural progenitor cells in high content imaging applications | |
| CN102985820A (zh) | 使用细胞系筛选线粒体katp调节剂的方法 | |
| Mir et al. | Two-dimensional surface plasmon resonance imaging system for cellular analysis | |
| Bernard‐Trifilo et al. | Analyzing FAK and Pyk2 in early integrin signaling events | |
| Xu et al. | Assessment of hepatotoxicity potential of drug candidate molecules including kinase inhibitors by hepatocyte imaging assay technology and bile flux imaging assay technology | |
| EP2456883A1 (en) | Label free methods related to phosphodiesterases | |
| Ahmed et al. | The Fate of Toxicological Studies: From Animal Models to Stem Cell-based Methods | |
| CN120359301A (zh) | 用于评价肾毒性的方法 |